metformin has been researched along with EHS Tumor in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anikin, IV | 1 |
| Goncharov, NV | 1 |
| Tyndyk, ML | 1 |
| Voĭshenko, NG | 1 |
| Pliss, GB | 1 |
| Zabezhinskiĭ, MA | 1 |
| Popovich, IG | 1 |
| Anisimov, VN | 1 |
1 other study available for metformin and EHS Tumor
| Article | Year |
|---|---|
[The effect of sodium fluoroacetate and metformin on the antitumor activity of cyclophosphamide on the autochthonous mice sarcoma model].
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Drug Synergism; Fluoroacetates; Metformin; Mice; M | 2014 |